<DOC>
	<DOCNO>NCT02670642</DOCNO>
	<brief_summary>The purpose study compare demand continuous treatment endoscopy negative subject gastroesophageal reflux disease ( GERD ) , esomeprazole 20-mg daily , regard willingness continue study result satisfactory treatment six-month long term management period , initial symptom relief .</brief_summary>
	<brief_title>Open , Randomised , Multi-center Study Demand Versus Continuous Esomeprazole Treatment Patient With GERD</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Symptoms suggestive GERD , heartburn predominant symptom ( described burn feeling , rise stomach lower part chest towards neck ) , longer 6 month . Heartburn occur 4 day last 7 day prior endoscopy . Or , PPI treatment start within last 7 day prior endoscopy , heartburn occur 4 day last 7 day prior start PPI treatment Male female , least 18 year age ( Austria , least 19 year age ) Have give write informed consent Ability read write ( literate ) 7 symptom free ( heartburn ) day last week prior randomisation ( day visit include ) Documented esophageal mucosal break History esophageal , gastric duodenal surgery , except closure oversew ulcer Chronic recurrent abdominal pain associate chronic recurrent bowel disturbance and/or bloating , opinion investigator likely due irritable bowel syndrome two follow criterion : Symptoms relieve defecation Symptoms associate change frequency stool Symptoms associate change form stool Any significant `` alarm symptom '' unintentional weight loss , haematemesis melaena , jaundice sign indicate serious malignant disease . Subjects current historical evidence follow diseases/conditions Zollinger Ellison syndrome Primary esophageal motility disorder ( ) i.e . achalasia , scleroderma , esophageal spasm Complications GERD esophageal stricture , ulcer and/or macroscopic Barrett 's metaplasia ( long 3 centimetre ) significant dysplastic change esophagus Evidence upper gastrointestinal malignancy screen endoscopy Gastric and/or duodenal ulcer within last 2 year Malabsorption Malignancy , significant cardiovascular , pulmonary , renal , pancreatic liver disease judge investigator Unstable diabetes mellitus . Stable diabetes control diet , oral agent insulin acceptable Cerebrovascular disease , cerebral ischemia , infarction , haemorrhage embolus Subjects use PPI 10 day last 28 day , prior endoscopy Use PPIs 5 day last 7 day prior endoscopy Subjects use daily H2receptor antagonist , prokinetics recommend treatment reflux symptom sucralfate 2 week prior endoscopy endoscopy visit 1 throughout study Need continuous concurrent therapy NSAIDs ( include selective COX II antagonist , salicylate ( unless &lt; 165 mg daily cardiovascular prophylaxis ) anticholinergic prostaglandin analogue phenytoin ketoconazole itraconazole warfarin vitamin K antagonists Pregnancy lactation . Women childbearing potential must maintain effective contraception study period judge investigator ( Austria : Women childbearing potential may include pregnancy status assess investigator prior entry monthly basis . For SouthAfrica Spain : Women childbearing potential may include pregnancy status assess investigator prior endoscopy ) Use investigational compound 28 day prior start study Requirement interpreter ( illiterate ) Alcohol and/or drug abuse condition associate poor compliance , include expect noncooperation , judge investigator Previous participation study Contraindications study drug , e.g . know suspected allergy esomeprazole constituent formulation . Known hypersensitivity substitute benzimidazole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>